FDA Approved New ADHD Drug Centanafadine
The drug offers a new non-stimulant treatment option for children and adults diagnosed with ADHD.
Updated on Sept. 28, 2026 in Mental Health
Live Poll
Do you feel new medication options are effectively improving mental health treatment for your household?
In July 2026, the FDA approved centanafadine, a norepinephrine-dopamine-serotonin reuptake inhibitor, to treat ADHD in pediatric and adult patients. This medication provides a new alternative for those who may not respond to traditional stimulant therapies.
Why it matters
Centanafadine offers a potential second-line option for patients who do not see sufficient benefit from stimulants, providing a new pathway for managing ADHD symptoms. It is particularly relevant for those seeking alternatives to current treatment standards.
A meta-analysis of four phase 3 trials and one phase 2b crossover study reported a Hedges' g effect size of 0.37 for symptom severity, compared to typical stimulant effect sizes of 0.8 to 1.0. While the findings support efficacy, the DEA scheduling for this drug remains under investigation.
The players
Food and Drug Administration
The federal agency responsible for protecting public health by ensuring the safety and efficacy of human drugs.
The details
Centanafadine acts as a norepinephrine-dopamine-serotonin reuptake inhibitor that does not rely on cytochrome P450 metabolism to function within the body. Capsules are designed to be flexible for administration, as they can be opened and sprinkled onto items like applesauce, yogurt, or orange juice. Patients should be aware that the medication is linked to a 2-fold increase in caffeine exposure, which may influence dietary habits.
Timeline
July 2026: The FDA officially approved centanafadine for the treatment of ADHD.
Health Landscape
This approval marks a formal step within the FDA drug approval process for non-stimulant psychiatric medications. It expands the therapeutic landscape for ADHD treatment beyond the standard stimulant-based care model.
Patients and caregivers should be aware of common side effects including appetite suppression, nausea, and rash, alongside a boxed warning for suicidal ideation. Discuss with your doctor whether this non-stimulant option is appropriate given your personal medical history and current caffeine intake.
The takeaway
Centanafadine provides a new non-stimulant alternative for ADHD management, though its specific effect size is lower than traditional stimulants. If you are exploring medication changes, discuss the potential for side effects and the required DEA scheduling status with your physician.
What happens next
The Drug Enforcement Administration is expected to determine the final controlled substance scheduling for centanafadine.
Further reading
For more on evolving treatment options and evidence-based approaches to care, visit our Mental Health section.
Source note: This article includes information reported by Pharmacytimes.
Live Poll
Do you feel new medication options are effectively improving mental health treatment for your household?
